Reviews/Ultra Processed Foods/Ultra-processed food raises all-cause mortality
Mortality Cancer · UPF-MC-01 · v2
The question is whether eating more ultra-processed food raises the chance of dying from any cause. In this set of papers, only two actually counted deaths, and both found that people who ate more ultra-processed food died more often. One study [20] was in people who had already had cancer, and the other [17] was a very large group of older adults described only in a short conference write-up. Both point the same way, but neither is the kind of experiment that can prove cause and effect, and one of them never states a plain all-cause number. Because the finding leans on just two observational studies in somewhat special groups, the panel treated the direction as credible while holding back on how strong or how general the effect is.
Only two papers in this corpus measured all-cause mortality directly, and both reported a positive association with higher ultra-processed food intake. [20], a prospective cohort of 802 long-term cancer survivors in the Moli-sani Study with 281 deaths over a median 14.6 years, reported a multivariable all-cause mortality HR of 1.48 (95% CI 1.07-2.03) that persisted after adjustment for overall diet quality. [17], a cohort of 96,607 adults aged 55 and over from the PLCO study with 28,700 all-cause deaths, concluded that higher ultra-processed food consumption increases the overall risk of mortality, though it reported explicit hazard ratios only for respiratory (HR 1.10; 95% CI 1.01-1.21) and COPD (HR 1.20; 95% CI 1.02-1.42) mortality. The remaining 18 papers measured surrogate or upstream outcomes such as energy intake and weight ([1], [3]), cardiometabolic risk factors ([6]), or were intervention, methods-validation, or protocol studies ([11], [12], [5]). The contested point: The division is over how much weight two observational studies can carry for a causal, general-population claim. Both cohorts agree in direction, but [20] is confined to cancer survivors and [17] is a conference abstract that states its all-cause conclusion qualitatively without a reported all-cause effect estimate.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ultra Processed Foods, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Only two of the twenty corpus papers measured all-cause mortality, and both are observational prospective cohorts; no randomized evidence tests the endpoint, so the association cannot be read as causal and residual confounding (diet quality, SES, lifestyle) remains the primary threat.
[20]'s all-cause mortality HR is derived in long-term cancer survivors (N=802) using postdiagnostic intake, a narrow and atypical population; extrapolating it to the general-population claim is an overreach.
Where it remains uncertain. [20]'s estimate comes from 802 long-term cancer survivors rather than the general population, and [17] gives explicit hazard ratios only for respiratory (1.10) and COPD (1.20) mortality, not an all-cause figure.
Aleatory
[20] rests on 281 deaths among 802 participants, so the HR of 1.48 carries a wide confidence interval (95% CI 1.07-2.03) and substantial random variation.
Epistemic
Just [20] and [17] of the twenty corpus papers measured all-cause mortality; the magnitude and generality of the effect cannot be pinned down from two studies.
Inferential
Both mortality studies are observational prospective cohorts, so the association cannot be read as causal and residual confounding by diet quality, SES and lifestyle remains open.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large (96,607) prospective cohort concluding higher UPF increases overall mortality risk, direction-concordant with [20].
“A total of 96,607 participants aged 55 years and over were obtained from Prostate, Lung, Colorectal and Ovarian (PLCO) cancer study”
Panel auditInternal validity: medium · scope of inference: UPF intake and mortality in 96,607 US adults aged 55+ from the PLCO trial, with respiratory mortality as the primary focus.Key limitations: all-cause HR not quantified · baseline-only diet measure · cause-specific focus on respiratory mortality
Provides an explicit, statistically significant all-cause mortality effect estimate (HR 1.48, CI excludes 1) robust to diet-quality adjustment, in a prospective cohort.
“Multivariable (including the MDS)-adjusted HRs of higher UPF consumption for all-cause and cancer mortality were 1.48 [95% confidence interval (CI), 1.07-2.03 for highest vs. lowest third]”
Panel auditInternal validity: medium · scope of inference: Postdiagnostic UPF intake and all-cause mortality in 802 long-term cancer survivors in the Moli-sani study.Key limitations: cancer-survivor population not general adults · observational confounding · modest sample
2 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direction of effect is supported by two concordant prospective cohorts, but observational-only design, thin and partly narrow-population evidence, and an unquantified all-cause estimate in the larger study hold confidence to the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
General-population all-cause mortality estimate. Both mortality cohorts are in special groups — cancer survivors [20] and a cancer-screening trial population [17] — so no unrestricted general-population all-cause figure exists in this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large prospective general-population cohort reporting a multivariable-adjusted all-cause mortality hazard ratio across levels of ultra-processed food intake.
Open question: Does higher ultra-processed food intake raise all-cause mortality in an unselected general-population cohort, with an explicit effect size? Why it is still open: The only two mortality studies are confined to cancer survivors [20] and a cancer-screening population [17], and [17] gives no all-cause estimate.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19